RXST on Nasdaq
RxSight, Inc.
In its 2026 annual report the company says: “RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight ® Light Adjustable Lens system is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery.”4 It is headquartered in Aliso Viejo, California.1 Its shares trade on Nasdaq under the symbol RXST.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with STAAR SURGICAL CO, Warby Parker or National Vision Holdings, Inc., or pick any stock.
- TickerRXST on Nasdaq1
- IndustryOphthalmic Goods1
- HeadquartersAliso Viejo, California1
- Incorporated inDE2
- Business address100 Columbia Street, Suite 120, Aliso Viejo, Ca 926562
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight ® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens ® (LAL ® /LAL+ ® , collectively the “LAL”), RxSight Light Delivery Device (“LDD™”) and related accessories. The LAL is a premium intraocular lens (“IOL”) made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (“UV”) light patterns generated by the LDD.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
76.6%Gross margin5
-35.8%Operating margin5
-29.0%Net margin5
-3.9%Revenue growth, 20255
-14.1%Return on equity5
-$19.3MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
RxLAL brought in 80% of the revenue RxSight, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| RxLAL | $54.1M | $96.5M | $108.1M |
| LDD | $32.1M | $39.7M | $20.7M |
| Service Warranty Service Contracts And Accessories | $2.9M | $3.7M | $5.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue17¢$31.5M
- Research and development21¢$38.5M
- Selling, general and admin62¢$112.7M
- Interest0¢$19.0K
- Income tax0¢$66.0K
Out of $134.5M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Sales | $134.5M | $139.9M | $89.1M |
| Cost of sales | $31.5M | $41.0M | $35.3M |
| Gross profit | $103.0M | $98.9M | $53.8M |
| Selling, general and administrative | $112.7M | $101.4M | $74.8M |
| Research and development | $38.5M | $34.4M | $29.1M |
| Total operating expenses | $151.2M | $135.8M | $103.8M |
| Loss from operations | -$48.2M | -$36.9M | -$50.1M |
| Interest expense | -$19.0K | -$21.0K | -$3.3M |
| Interest and other income | $9.3M | $9.5M | $6.6M |
| Loss on extinguishment of term loan | $0 | $0 | -$1.8M |
| Loss before income taxes | -$38.9M | -$27.4M | -$48.6M |
| Income tax expense | $66.0K | $50.0K | $20.0K |
| Net loss | -$38.9M | -$27.5M | -$48.6M |
| Unrealized (loss) gain on short-term investments | -$136.0K | $180.0K | $83.0K |
| Foreign currency translation gain (loss) | $23.0K | -$9.0K | $7.0K |
| Total other comprehensive (loss) income | -$113.0K | $171.0K | $90.0K |
| Comprehensive loss | -$39.1M | -$27.3M | -$48.5M |
| Attributable to common stock, basic | -$0.95 | -$0.71 | -$1.41 |
| Attributable to common stock, diluted | -$0.95 | -$0.71 | -$1.41 |
| Attributable to common stock, basic | 40.9M shares | 38.9M shares | 34.5M shares |
| Attributable to common stock, diluted | 40.9M shares | 38.9M shares | 34.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $19.9M | $16.7M |
| Short-term investments | $208.2M | $220.5M |
| Accounts receivable | $23.4M | $30.1M |
| Inventories, net | $31.6M | $22.0M |
| Prepaid and other current assets | $4.4M | $4.5M |
| Total current assets | $287.5M | $293.8M |
| Property and equipment, net | $13.1M | $12.4M |
| Operating leases right-of-use assets | $10.0M | $11.2M |
| Restricted cash | $750.0K | $750.0K |
| Other assets | $590.0K | $360.0K |
| Total assets | $311.8M | $318.6M |
| Accounts payable | $5.3M | $4.5M |
| Accrued expenses and other current liabilities | $19.8M | $20.4M |
| Lease liabilities | $1.2M | $974.0K |
| Total current liabilities | $26.3M | $25.9M |
| Long-term lease liabilities | $9.9M | $11.3M |
| Other long-term liabilities | $0 | $127.0K |
| Total liabilities | $36.1M | $37.3M |
| Common stock, $0.001 par value, 900,000,000 shares authorized, 41,242,005 shares issued and outstanding as of December 31, 2025 and 40,428,220 Shares issued and outstanding as of December 31, 2024 | $41.0K | $40.0K |
| Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding | $0 | $0 |
| Additional paid-in capital | $936.6M | $903.1M |
| Accumulated other comprehensive loss | $53.0K | $166.0K |
| Accumulated deficit | -$661.0M | -$622.1M |
| Total stockholders' equity | $275.7M | $281.2M |
| Total liabilities and stockholders' equity | $311.8M | $318.6M |
| Common stock par value (USD per share) | $0.00 | $0.00 |
| Common stock, authorized (in shares) | 900.0M shares | 900.0M shares |
| Common stock issued (in shares) | 41.2M shares | 40.4M shares |
| Common stock outstanding (in shares) | 41.2M shares | 40.4M shares |
| Preferred stock par value per share | $0.00 | $0.00 |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares |
| Preferred Shares Issued | 0 shares | 0 shares |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $19.9M | $16.7M |
| Short-term investments | $208.2M | $220.5M |
| Accounts receivable | $23.4M | $30.1M |
| Inventories, net | $31.6M | $22.0M |
| Prepaid and other current assets | $4.4M | $4.5M |
| Total current assets | $287.5M | $293.8M |
| Property and equipment, net | $13.1M | $12.4M |
| Operating leases right-of-use assets | $10.0M | $11.2M |
| Restricted cash | $750.0K | $750.0K |
| Other assets | $590.0K | $360.0K |
| Total assets | $311.8M | $318.6M |
| Accounts payable | $5.3M | $4.5M |
| Accrued expenses and other current liabilities | $19.8M | $20.4M |
| Lease liabilities | $1.2M | $974.0K |
| Total current liabilities | $26.3M | $25.9M |
| Long-term lease liabilities | $9.9M | $11.3M |
| Other long-term liabilities | $0 | $127.0K |
| Total liabilities | $36.1M | $37.3M |
| Common stock, $0.001 par value, 900,000,000 shares authorized, 41,242,005 shares issued and outstanding as of December 31, 2025 and 40,428,220 Shares issued and outstanding as of December 31, 2024 | $41.0K | $40.0K |
| Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding | $0 | $0 |
| Additional paid-in capital | $936.6M | $903.1M |
| Accumulated other comprehensive loss | $53.0K | $166.0K |
| Accumulated deficit | -$661.0M | -$622.1M |
| Total stockholders' equity | $275.7M | $281.2M |
| Total liabilities and stockholders' equity | $311.8M | $318.6M |
| Common stock par value (USD per share) | $0.00 | $0.00 |
| Common stock, authorized (in shares) | 900.0M shares | 900.0M shares |
| Common stock issued (in shares) | 41.2M shares | 40.4M shares |
| Common stock outstanding (in shares) | 41.2M shares | 40.4M shares |
| Preferred stock par value per share | $0.00 | $0.00 |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares |
| Preferred Shares Issued | 0 shares | 0 shares |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$38.9M | -$27.5M | -$48.6M |
| Depreciation and amortization | $3.3M | $3.6M | $4.1M |
| Provision for bad debts | $32.0K | $34.0K | $0 |
| Amortization of debt issuance costs and premium | $0 | $0 | $287.0K |
| Loss on extinguishment of debt | $0 | $0 | $1.8M |
| Amortization of discount on short-term investments | -$8.5M | -$9.0M | -$6.1M |
| Stock-based compensation | $31.6M | $24.6M | $15.7M |
| Provision for excess and obsolete inventory | $1.9M | $404.0K | $164.0K |
| Accounts receivable | $6.7M | -$9.8M | -$9.3M |
| Inventories | -$11.5M | -$5.0M | -$2.7M |
| Prepaid and other assets | $1.2M | -$1.2M | -$397.0K |
| Accounts payable | $627.0K | $946.0K | $1.2M |
| Accrued expenses and other liabilities | -$1.9M | $5.9M | $2.3M |
| Net cash used in operating activities | -$15.5M | -$16.9M | -$41.6M |
| Purchases of property and equipment | -$3.8M | -$5.4M | -$4.8M |
| Maturity of short-term investments | $260.0M | $243.0M | $255.0M |
| Purchase of short-term investments | -$239.3M | -$336.9M | -$272.3M |
| Net cash (used in) provided by investing activities | $16.9M | -$99.3M | -$22.1M |
| Proceeds from term loan | $0 | $0 | $20.0M |
| Repayment of term loan | $0 | $0 | -$60.0M |
| Proceeds from issuance of common stock from public offering | $0 | $108.1M | $54.0M |
| Proceeds from issuance of common stock for at-the-market offerings | $0 | $42.4M | |
| Proceeds from Issuance of Common Stock | $4.0M | $20.8M | $9.5M |
| Payments for employee taxes related to stock compensation | -$2.1M | -$4.8M | -$1.4M |
| Principal payments on finance lease liabilities | -$26.0K | -$61.0K | -$153.0K |
| Payments of deferred offering costs | $0 | -$768.0K | -$622.0K |
| Payments of debt issuance costs | $0 | $0 | -$2.2M |
| Net cash provided by financing activities | $1.9M | $123.3M | $61.5M |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | $3.0K | -$9.0K | $6.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $3.2M | $7.1M | -$2.2M |
| Operating cash flows from operating leases | $2.6M | $2.2M | $2.2M |
| Cash paid for income taxes | $58.0K | $24.0K | $8.0K |
| Cash paid for interest on term loan | $0 | $0 | $3.5M |
| Operating lease | $29.0K | $10.0M | $46.0K |
| Operating lease | $29.0K | $10.0M | $46.0K |
| Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities | $421.0K | $545.0K | $282.0K |
| Deferred offering costs included in accounts payable and accrued liabilities | $0 | $0 | $145.0K |
| Reclassification of deferred financing costs | $0 | $768.0K | $1.4M |
No quarter-by-quarter statement was filed.
Corporate structure
RxSight, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of RxSight, Inc.
- Point72 Asset Management, L.P. Filed SCHEDULE 13G on RxSight, Inc., latest Aug 19, 2026
- MILLENNIUM MANAGEMENT LLC Filed SCHEDULE 13G/A on RxSight, Inc., latest Aug 4, 2026 (3 filings since Jul 15, 2025)
- BlackRock Portfolio Management LLC Filed SCHEDULE 13G on RxSight, Inc., latest Jul 17, 2026
- Artisan Partners Limited Partnership Filed SCHEDULE 13G/A on RxSight, Inc., latest May 13, 2026 (6 filings since Feb 12, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on RxSight, Inc., latest Mar 27, 2026 (3 filings since Nov 4, 2024)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on RxSight, Inc., latest Nov 14, 2025 (3 filings since Feb 14, 2024)
- BlackRock Filed SCHEDULE 13G/A on RxSight, Inc., latest Oct 17, 2025 (4 filings since Jan 29, 2024)
- Bank of America Filed SCHEDULE 13G/A on RxSight, Inc., latest Aug 13, 2025 (2 filings since Feb 14, 2025)
- Divisadero Street Capital Management, LP Filed SCHEDULE 13G/A on RxSight, Inc., latest Aug 13, 2025 (2 filings since Apr 8, 2025)
- LORD, ABBETT & CO. LLC Filed SCHEDULE 13G/A on RxSight, Inc., latest Feb 13, 2025 (2 filings since Feb 14, 2024)
- Longitude Capital Partners II, LLC Filed SC 13D/A on RxSight, Inc., latest Aug 18, 2023 (2 filings since Jun 5, 2023)
- ORBIMED ADVISORS LLC Filed SC 13G/A on RxSight, Inc., latest Feb 14, 2023 (2 filings since Feb 11, 2022)
- RxSight, Inc. Aliso Viejo, California
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What RxSight, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $39.6M5 Dec 31, 2025 | $37.8M5 Dec 31, 2024 | +4.7% |
| Accumulated depreciation | $26.6M5 Dec 31, 2025 | $25.4M5 Dec 31, 2024 | +4.5% |
| Property and equipment, net | $13.1M5 Dec 31, 2025 | $12.4M5 Dec 31, 2024 | +5.2% |
| Finance-lease assets | $81.0K5 Dec 31, 2025 | $125.0K5 Dec 31, 2024 | −35.2% |
| Operating-lease assets (leased space) | $10.0M5 Dec 31, 2025 | $11.2M5 Dec 31, 2024 | −11.2% |
Real estate and locations
| Item | Latest | A year before | Change |
|---|---|---|---|
| Area of real estate | 13,183 sq ft5 Nov 6, 2024 |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $19.9M5 Dec 31, 2025 | $16.7M5 Dec 31, 2024 | +19.4% |
| Marketable securities, current | $208.2M5 Dec 31, 2025 | $220.5M5 Dec 31, 2024 | −5.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $31.6M5 Dec 31, 2025 | $22.0M5 Dec 31, 2024 | +43.4% |
| Raw materials | $8.3M5 Dec 31, 2025 | $7.1M5 Dec 31, 2024 | +17.3% |
| Work in process | $3.6M5 Dec 31, 2025 | $3.5M5 Dec 31, 2024 | +2.0% |
| Finished goods | $21.6M5 Dec 31, 2025 | $12.0M5 Dec 31, 2024 | +79.9% |
Properties, in its own words
We currently lease five facilities which includes our headquarters, manufacturing, research and development and administrative offices in Aliso Viejo, California. The facility leases are for approximately 150,000 square feet in the aggregate. The current leases on our five facilities expire on January 31, 2031, with two options to extend for five years each. We believe that our facilities are adequate to meet our current needs.
Item 2 of the 10-K filed Feb 25, 2026.4
Leadership
Who has led RxSight, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerAziz Mottiwala Jul 24, 2026 to now12
- Chief executive officerRonald M. Kurtz Md. Feb 13, 2023 to Jul 24, 202613
- PresidentAziz Mottiwala Jul 24, 2026 to now12
- PresidentRonald M. Kurtz Md. Feb 13, 2023 to Jul 24, 202613
- Chief financial officerMark Wilterding Jan 30, 2026 to now14
- Chief financial officerShelley B. Thunen Jul 29, 2021 to Jul 2, 202415
- Chief operating officerIlya Goldshleger Jul 29, 2021 to now16
Board members and other officers (18)
- Chief Customer OfficerScott Gaines Jan 15, 2026 to now17
- OfficerShelley B. Thunen Jul 16, 2024 to now18
- OfficerIlya Goldshleger Aug 6, 2024 to now19
- Chief Commercial OfficerEric Weinberg Jul 29, 2021 to now20
- OfficerRonald M. Kurtz Md. Jul 29, 2021 to now21
- Board memberAziz Mottiwala Jul 24, 2026 to now12
- Board memberRaymond W. Cohen Aug 4, 2025 to now22
- Board memberShweta Maniar Jan 5, 2022 to now23
- Board memberTamara Fountain Jan 5, 2022 to now24
- Board memberBakker Juliet Tammenoms Jul 29, 2021 to now25
- Board memberBruce C. Robertson Jul 29, 2021 to Aug 5, 202126
- Board memberJesse Anderson Corley Jul 29, 2021 to now27
- Board memberRichard M. Wolfen Jul 29, 2021 to Aug 5, 202128
- Board memberRonald M. Kurtz Md. Jul 29, 2021 to now21
- Board memberWilliam J. Link Phd. Jul 29, 2021 to now29
- Board memberJulie Andrews Aug 5, 2021 to now30
- Board memberRobert J. Palmisano Aug 5, 2021 to now31
- Board memberRobert Keith Warner Aug 5, 2021 to now32
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- CALHOUN VISION INCJul 30, 2002 to Mar 20, 20142
Timeline
- Aug 5, 20268-K Results of operations33
- Jul 24, 2026New chief executive Aziz Mottiwala becomes CEO12
- Jul 15, 20268-K Executive or director change; Regulation FD disclosure34
- Jul 6, 20268-K Results of operations35
- Jul 6, 20268-K Entered a material agreement; Regulation FD disclosure36
- Jun 16, 20268-K Shareholder vote37
- May 6, 20268-K Results of operations38
- Mar 19, 20268-K Executive or director change39
- Feb 25, 20268-K Results of operations40
- Jan 12, 20268-K Results of operations; Executive or director change; Regulation FD disclosure41
- Dec 23, 20258-K Executive or director change; Regulation FD disclosure42
- Dec 22, 20258-K Executive or director change; Regulation FD disclosure43
- Dec 19, 20258-K Executive or director change44
- Feb 13, 2023New chief executive Ronald M. Kurtz Md. becomes CEO13
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.24) a share, on Nov 5, 2025.45
When it reported results
- Aug 5, 2026Reported quarterly or annual results33
- Jul 6, 2026Reported quarterly or annual results35
- May 6, 2026Reported quarterly or annual results38
- Feb 25, 2026Reported quarterly or annual results40
- Jan 12, 2026Reported quarterly or annual results41
- Nov 5, 2025Reported quarterly or annual results46
- Aug 7, 2025Reported quarterly or annual results47
- Jul 8, 2025Reported quarterly or annual results48
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
395 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 49 major events, 171 insider forms, 34 large holders, 120 other. The latest 20:
- Sep 16, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 8, 2026SC TO-I/A EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Aug 25, 2026SC TO-I/A EDGAR
- Aug 19, 2026SCHEDULE 13G EDGAR
- Aug 18, 2026144 EDGAR
- Aug 10, 2026SC TO-I EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
The 395 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
91 open-market trades by officers, directors and large owners since October 2021: 9 buys and 82 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Kurtz Ronald M MDChief Medical Officer | Sale | 5,100 | $6.96 | $35.5K | Form 4 |
| Sep 2, 2026 | Wilterding MarkChief Financial Officer | Sale | 7,765 | $6.96 | $54.0K | Form 4 |
| Sep 2, 2026 | Goldshleger IlyaChief Operating Officer | Sale | 2,041 | $6.96 | $14.2K | Form 4 |
| Sep 2, 2026 | Weinberg EricSee remarks | Sale | 2,041 | $6.96 | $14.2K | Form 4 |
| Mar 12, 2025 | Fountain TamaraDirector | Sale | 7,000 | $25.71 | $180.0K | Form 4 |
| Jan 22, 2025 | Maniar ShwetaDirector | Sale | 3,519 | $30.87 | $108.6K | Form 4 |
| Jan 16, 2025 | Corley Jesse AndersonDirector | Buy | 1,767 | $31.13 | $55.0K | Form 4 |
| Jan 15, 2025 | Corley Jesse AndersonDirector | Buy | 1,443 | $31.19 | $45.0K | Form 4 |
| Nov 29, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,105 | $46.08 | $143.1K | Form 4 |
| Nov 26, 2024 | Maniar ShwetaDirector | Sale | 3,782 | $45.88 | $173.5K | Form 4 |
| Nov 26, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,100 | $45.88 | $142.2K | Form 4 |
| Nov 22, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,100 | $45.00 | $139.5K | Form 4 |
| Nov 18, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,100 | $45.00 | $139.5K | Form 4 |
| Nov 15, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 4,875 | $46.00 | $224.2K | Form 4 |
| Nov 13, 2024 | Corley Jesse AndersonDirector | Buy | 11,365 | $44.92 | $510.5K | Form 4 |
| Nov 12, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 1,330 | $46.13 | $61.4K | Form 4 |
| Nov 12, 2024 | Corley Jesse AndersonDirector | Buy | 11,111 | $45.37 | $504.1K | Form 4 |
| Nov 7, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,100 | $55.00 | $170.5K | Form 4 |
| Nov 4, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,100 | $51.04 | $158.2K | Form 4 |
| Oct 30, 2024 | Goldshleger IlyaChief Operating Officer | Sale | 3,105 | $51.91 | $161.2K | Form 4 |
All 91 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Point72 Asset Management, L.P.SCHEDULE 13G, 1 filing Aug 19, 202649
- MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 3 filings Jul 15, 2025 to Aug 4, 202650
- BlackRock Portfolio Management LLCSCHEDULE 13G, 1 filing Jul 17, 202651
- Artisan Partners Limited PartnershipSCHEDULE 13G/A, 6 filings Feb 12, 2024 to May 13, 202652
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Nov 4, 2024 to Mar 27, 202653
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 3 filings Feb 14, 2024 to Nov 14, 202554
- BlackRockSCHEDULE 13G/A, 4 filings Jan 29, 2024 to Oct 17, 202555
- Bank of AmericaSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Aug 13, 202556
- Divisadero Street Capital Management, LPSCHEDULE 13G/A, 2 filings Apr 8, 2025 to Aug 13, 202557
- LORD, ABBETT & CO. LLCSCHEDULE 13G/A, 2 filings Feb 14, 2024 to Feb 13, 202558
- Longitude Capital Partners II, LLCSC 13D/A, 2 filings Jun 5, 2023 to Aug 18, 202359
- ORBIMED ADVISORS LLCSC 13G/A, 2 filings Feb 11, 2022 to Feb 14, 202360
- Anthony TamerSC 13G, 1 filing Feb 14, 202261
- Richard M. WolfenSC 13G, 1 filing Feb 14, 202262
- RxSight I, LLCSC 13G, 1 filing Feb 14, 202263
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Ron KurtzM.D. | 63 | $630.6K | $4.7M64 |
| 2025 | Eric Weinberg | 65 | $520.4K | $2.9M64 |
| 2025 | Shelley Thunen | $520.4K | $2.9M64 | |
| 2025 | Ilya GoldshlegerPh.D. | $520.4K | $2.9M64 | |
| 2025 | Scott Gaines | 57 | $401.7K | $1.4M64 |
| 2024 | Chief Executive OfficerPresident and Director | $678.3K | $7.0M64 | |
| 2024 | Chief Operating Officer | $503.8K | $5.8M64 | |
| 2024 | Chief Business Development Officer | $503.8K | $5.8M64 | |
| 2024 | Former Chief Financial Officer | $503.8K | $5.8M64 | |
| 2023 | Chief Executive OfficerPresident and Director | $633.3K | $3.1M64 | |
| 2023 | Former Chief Financial Officer | $454.2K | $1.9M64 | |
| 2023 | Chief Operating Officer | $454.2K | $1.9M64 | |
| 2023 | Chief Business Development Officer | $454.2K | $1.7M64 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 5,790,408 | $27.9M | 0.0% | +2,603,316 |
| Millennium Management LLC | 3,030,287 | $14.6M | 0.0% | +970,828 |
| No Street GP LP | 2,055,000 | $9.9M | 0.6% | +55,000 |
| Nomura Holdings Inc | 2,000,060 | $9.6M | 0.0% | No change |
| D. E. Shaw & Co., Inc. | 1,985,215 | $9.6M | 0.0% | +25,483 |
| Vanguard Capital Management LLC | 1,675,582 | $8.1M | 0.0% | −17,353 |
| Aqr Capital Management LLC | 1,533,826 | $7.4M | 0.0% | +897,697 |
| Federated Hermes, Inc. | 1,201,195 | $5.8M | 0.0% | +120,483 |
| Two Sigma Investments, LP | 1,147,048 | $5.5M | 0.0% | −153,212 |
| Healthcare Of Ontario Pension Plan Trust Fund | 1,131,400 | $5.5M | 0.0% | No change |
| UBS Group AG | 1,016,066 | $4.9M | 0.0% | +776,610 |
| Jacobs Levy Equity Management, Inc | 998,569 | $4.8M | 0.0% | −67,752 |
| Marshall Wace, Llp | 995,916 | $4.8M | 0.0% | +983,191 |
| Geode Capital Management, LLC | 984,978 | $4.7M | 0.0% | +65,085 |
| State Street Corp | 851,512 | $4.1M | 0.0% | +50,189 |
| Point72 Asset Management, L.P. | 778,252 | $3.8M | 0.0% | +44,945 |
| Grandeur Peak Global Advisors, LLC | 722,440 | $3.5M | 0.8% | +256,848 |
| Schonfeld Strategic Advisors LLC | 701,417 | $3.4M | 0.0% | +509,717 |
| Citadel Advisors LLC | 700,736 | $3.4M | 0.0% | −417,983 |
| Trexquant Investment LP | 607,935 | $2.9M | 0.0% | +470,948 |
| Goldman Sachs Group Inc | 546,154 | $2.6M | 0.0% | +50,450 |
| Deutsche Bank Ag\ | 540,208 | $2.6M | 0.0% | −422,104 |
| Norges Bank | 500,000 | $2.4M | 0.0% | New |
| Qube Research & Technologies Ltd | 491,550 | $2.4M | 0.0% | +366,420 |
| Bank Of America Corp /de/ | 485,298 | $2.3M | 0.0% | −724,741 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How RxSight, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRxSight, Inc.1
- CIK0001111485
- Employer ID (EIN)94-32688014
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3851 Ophthalmic Goods1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address100 Columbia Street, Suite 120, Aliso Viejo, CA 926561
- Phone949-521-78221
- Shares outstanding41,593,256 as of Jul 31, 202610
- Public float$503.8M as of Jun 30, 20254
- AuditorErnst & Young LLP, Irvine, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJul 30, 20021
- Filings468 in all: 4 (184), 144 (79), 8-K (48), 3 (22), 10-Q (16), SCHEDULE 13G/A (10), SC 13G (8), SC 13G/A (8)1
All 45 form types
S-8 (7), SCHEDULE 13G (7), 10-K (5), 424B5 (5), CORRESP (5), D/A (5), DEF 14A (5), DEFA14A (5), D (4), REGDEX (4), ARS (3), EFFECT (3), SD (3), UPLOAD (3), 4/A (2), 8-K/A (2), S-1/A (2), SC 13D/A (2), SC TO-I/A (2), SEC STAFF LETTER (2), 10-K/A (1), 144/A (1), 424B4 (1), 8-A12B (1), ARS/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), POSASR (1), PRE 14A (1), S-1 (1), S-3 (1), S-3ASR (1), SC 13D (1), SC TO-I (1)
- Latest filingsAnnual report (10-K) Feb 25, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, $0.001 par value per share | RXST | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks RxSight, Inc. names in Item 1A of its 10-K filed Feb 25, 2026: 75 risks under these headings, as written.4
- Risks related to our business and products
- If we fail to effectively train our sales force, increase our sales and marketing capabilities or develop broad brand awareness in a cost-effective manner, our growth will be impeded, and our business will suffer.
- We have a history of net losses, and we expect to continue to incur losses in the future. If we ever achieve profitability, we may not be able to sustain it.
- In order to support our continued operations and the growth of our business, we may seek to raise additional capital, which may not be available to us on acceptable terms, or at all.
- Global economic, political and market conditions, including downgrades of the U.S. credit rating, and inflation may adversely affect our business, results of operations and financial condition, including our revenue growth and profitability.
- Deterioration in the economic conditions globally has resulted in instability in global financial markets, including: inflation and rising interest rates and instability in the capital markets.
- Changes in U.S. trade policy, including recently announced tariffs, could have a material adverse impact on our business, financial condition, and results of operations.
- We currently maintain all of our cash, cash equivalents and short-term investments in one financial institution and, therefore, our cash, cash equivalents and short-term investments could be adversely affected if the financial institution in which we hold our cash, cash equivalents and short-term investments fails.
- Our success depends in large part on our RxSight system. If we are unable to successfully market and sell our RxSight system, our business prospects will be significantly harmed, and we may be unable to achieve revenue growth.
- Adoption of our products depends upon appropriate training for doctors, and inadequate training may lead to negative patient outcomes, affect adoption of our products and adversely affect our business.
- The commercial success of our RxSight system will depend upon attaining significant market acceptance of these products among patients and doctors.
- We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain significant market penetration or improve our results of operations.
The other 64 risks
- Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.
- If our facilities become damaged or inoperable, or if we are required to vacate a facility, we may be unable to manufacture our products or we may experience delays in production or an increase in costs, which could adversely affect our results of operations.
- Technological change may adversely affect sales of our products and may cause our products to become obsolete.
- Uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products may result in harm to our business and reputation.
- Results of earlier studies may not be predictive of future clinical trial results, and planned studies may not establish an adequate safety or efficacy profile for our RxSight system and other planned or future products, which would affect market acceptance of our RxSight system.
- If our clinical trials are unsuccessful or significantly delayed, or if we do not complete our clinical trials, our business may be harmed.
- Unauthorized third parties may seek to access our devices or other products and services, or related devices, products, and services, and modify or use them in a way inconsistent with our FDA clearances and approvals, which may create risks to users.
- Our IT systems, contractors or consultants or potential future collaborators, may fail or suffer actual or suspected security or privacy breaches or incidents or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm our brand and cause material disruption to our operations.
- We may expend our limited resources to pursue a particular product or indication and fail to capitalize on products or indications that may be more profitable or for which there is a greater likelihood of success.
- We may not be able to develop, license or acquire new products, enhance the capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business, financial condition and results of operations.
- If we fail to identify, acquire and develop other products, we may be unable to grow our business.
- We may acquire other companies or technologies, which could fail to result in a commercial product or increased revenue, divert our management’s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.
- Coverage and adequate reimbursement and/or the ability of patients to pay for the difference between the price charged by practices and the reimbursement amount may not be available for our products in sufficient markets, which could diminish our sales or affect our ability to sell our products.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our products. The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm us and our ability to sell our products.
- We intend to expand sales of our products internationally in the future, but we may experience difficulties in obtaining regulatory clearance or approval or in successfully marketing our products internationally even if approved. A variety of risks associated with marketing our products internationally could materially adversely affect our business.
- We may not be able to achieve or maintain satisfactory pricing and margins for our products.
- The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate.
- To the extent changes to state regulations and interpretation of the practice of optometry, changes to insurance coverage and government reimbursement rates for our products and related procedures and/or changes in medical or professional malpractice insurance coverage for doctors who perform procedures using our products are implemented, such changes could affect the adoption of our products and our future revenue.
- Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.
- We have expanded, and may continue to expand, our organization, including expanding our sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
- Certain of our operating results and financial metrics may be difficult to predict as a result of seasonality.
- Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.
- Risks related to intellectual property
- If we are unable to obtain, maintain, protect and enforce patent and other intellectual property protection for our technology and products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
- Patent terms may be inadequate to protect our competitive position on technology for an adequate amount of time.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
- Our future reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
- We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.
- We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.
- Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
- Our rights to develop and commercialize our products are subject, in part, to the terms and conditions of licenses granted to us by others.
- In the future, we may enter agreements involving licenses or collaborations that provide for access or sharing of intellectual property. If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future products.
- We may not be successful in obtaining necessary rights to any products we may develop through acquisitions and in-licenses.
- We may be subject to claims challenging the inventorship of our patents and other intellectual property.
- If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed.
- Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- We may not be able to protect our intellectual property rights throughout the world, which could impair our business.
- Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
- Our use of “open source” software could subject our proprietary software to general release, adversely affect our ability to sell our products and subject us to possible litigation.
- If our trademarks, service marks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.
- Risks related to government regulation
- If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.
- Our products and operations are subject to extensive government regulation and oversight in the U.S.
- Material modifications to our products may require new 510(k) clearances or pre-market approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.
- Obtaining and maintaining regulatory approval of our current and future products in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our current and future products in other jurisdictions. The FDA and other comparable foreign regulatory authorities may not accept data from clinical trials conducted in locations outside of their jurisdiction.
- Our products may be subject to recalls after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation and adversely affect our business.
- If we, or our suppliers, fail to comply with the FDA’s QMSR or other applicable foreign regulations, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.
- Healthcare reform initiatives and other administrative and legislative proposals may adversely affect our business, financial condition, results of operations and cash flows in our key markets.
- If we fail to comply with U.S. federal and state fraud and abuse and other healthcare laws and regulations, we could face substantial penalties and our business operations and financial condition could be adversely affected.
- Changes in the CMS fee schedules may harm our revenue and operating results.
- Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of our planned or future products and to manufacture, market and distribute our products after clearance or approval is obtained.
- Compliance with the EU Medical Device Regulation, applicable regulations in the United Kingdom, and other applicable foreign regulations, as well as any changes to existing regulations, may be costly and disruptive to our business, and expose us to increased liability.
- Our clinical trials may fail to demonstrate competent and reliable evidence of the safety and effectiveness of our products, which would prevent or delay commercialization of our products in development.
- Defects or failures associated with our products could lead to recalls, safety alerts or litigation, as well as significant costs and negative publicity.
- Our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- Environmental health and safety laws may result in liabilities, expenses and restrictions on our operations. Failure to comply with environmental laws and regulations could subject us to significant liability.
- We face risks related to our collection and use of data, which could result in investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data and security protection practices.
- Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Our global operations can expose us to numerous and sometimes conflicting legal and regulatory requirements, including to anti-bribery and anti-corruption laws, such as the FCPA and the U.K. Bribery Act, and violation of these requirements could result in substantial penalties and prosecution and harm our business.
- Risks related to reliance on third parties
- From time to time, we engage outside parties to perform services related to certain of our clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our products.
- We and our component suppliers may not meet regulatory quality standards applicable to our manufacturing processes, which could have an adverse effect on our business, financial condition and results of operations.
- We depend upon third parties, including single and sole source suppliers, to manufacture certain components and subcomponents of the RxSight system making us vulnerable to supply disruptions and price fluctuations.
- The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.
- Risks related to our common stock
- The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.
- If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.
Legal proceedings
Securities Class Actions
On July 22, 2025, a putative securities class action complaint was filed in the U.S. District Court for the Central District of California against the Company and certain of its officers, captioned Makaveev v. RxSight, Inc., et al., No. 8:25-cv-01596. The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, alleging that the defendants made materially false and misleading statements and omitted material adverse facts regarding demand for our products and financial guidance. On September 16, 2025, a related putative securities class action complaint was filed in the U.S. District Court for the Central District of California against us and certain of our officers, captioned Gémesi v. RxSight, Inc., et al., No. 25-cv-02093. On October 6, 2025, the court entered an order consolidating the Makaveev and Gémesi actions, appointing a lead plaintiff and approving selection of lead counsel, and re-captioning the case as In re RxSight Securities Litigation, No. 8:25-cv-01596-FWS-KES. . A consolidated, amended complaint was filed on December 12, 2025. Defendants’ motion to dismiss was filed on February 13, 2026. The plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys’ fees.
Shareholder Derivative Actions
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARRxSight, Inc. filings on SEC EDGAR
- 2SEC EDGARRxSight, Inc. filings on SEC EDGAR
- 3
- 4
- 5SEC EDGARRxSight, Inc. 10-K for fiscal 2025
- 6SEC EDGARRxSight, Inc. 10-K for fiscal 2020
- 7SEC EDGARRxSight, Inc. 10-K for fiscal 2021
- 8SEC EDGARRxSight, Inc. 10-K for fiscal 2022
- 9SEC EDGARRxSight, Inc. 10-Q for fiscal 2026
- 10SEC EDGARRxSight, Inc. 10-Q for fiscal 2026
- 11SEC EDGARRxSight, Inc. 10-K for fiscal 2022
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARScott Gaines, Chief Customer Officer
- 18SEC EDGARShelley B. Thunen, Officer
- 19SEC EDGARIlya Goldshleger, Officer
- 20
- 21SEC EDGARRonald M. Kurtz Md., Officer
- 22SEC EDGARRaymond W. Cohen, Board member
- 23SEC EDGARShweta Maniar, Board member
- 24SEC EDGARTamara Fountain, Board member
- 25
- 26SEC EDGARBruce C. Robertson, Board member
- 27SEC EDGARJesse Anderson Corley, Board member
- 28SEC EDGARRichard M. Wolfen, Board member
- 29SEC EDGARWilliam J. Link Phd., Board member
- 30SEC EDGARJulie Andrews, Board member
- 31SEC EDGARRobert J. Palmisano, Board member
- 32SEC EDGARRobert Keith Warner, Board member
- 33SEC EDGARResults of operations
- 34
- 35SEC EDGARResults of operations
- 36
- 37SEC EDGARShareholder vote
- 38SEC EDGARResults of operations
- 39SEC EDGARExecutive or director change
- 40SEC EDGARResults of operations
- 41
- 42
- 43
- 44SEC EDGARExecutive or director change
- 45NasdaqNasdaq calendar
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64